Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients
Clinical trial NCT05806268 · COMPLETED
Trial details
- NCT number
- NCT05806268
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2021-07-30
- Primary completion
- 2022-03-28
- Enrollment
- 214
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.